TrialBritish journal of haematology2016

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Nancy Levin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.